Chartwell Investment Partners LLC Purchases 7,447 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

Chartwell Investment Partners LLC lifted its position in Vera Therapeutics, Inc. (NASDAQ:VERA) by 63.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,172 shares of the company’s stock after purchasing an additional 7,447 shares during the quarter. Chartwell Investment Partners LLC’s holdings in Vera Therapeutics were worth $847,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. AlphaCentric Advisors LLC bought a new stake in shares of Vera Therapeutics in the third quarter worth about $332,000. China Universal Asset Management Co. Ltd. grew its position in Vera Therapeutics by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,545 shares of the company’s stock worth $466,000 after acquiring an additional 4,118 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Vera Therapeutics by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company’s stock worth $86,000 after acquiring an additional 350 shares in the last quarter. Eastern Bank purchased a new position in Vera Therapeutics in the third quarter worth about $2,477,000. Finally, Handelsbanken Fonder AB grew its position in Vera Therapeutics by 19.0% in the third quarter. Handelsbanken Fonder AB now owns 13,800 shares of the company’s stock worth $610,000 after acquiring an additional 2,200 shares in the last quarter. 99.21% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, CEO Marshall Fordyce sold 15,625 shares of the company’s stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $37.50, for a total transaction of $585,937.50. Following the transaction, the chief executive officer now directly owns 307,972 shares of the company’s stock, valued at approximately $11,548,950. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, Director Beth C. Seidenberg sold 15,000 shares of the company’s stock in a transaction on Monday, October 28th. The stock was sold at an average price of $48.03, for a total value of $720,450.00. Following the transaction, the director now directly owns 131,553 shares of the company’s stock, valued at $6,318,490.59. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marshall Fordyce sold 15,625 shares of the company’s stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $37.50, for a total transaction of $585,937.50. Following the completion of the sale, the chief executive officer now directly owns 307,972 shares in the company, valued at approximately $11,548,950. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 104,398 shares of company stock valued at $4,376,163 over the last 90 days. Corporate insiders own 21.70% of the company’s stock.

Vera Therapeutics Stock Down 0.3 %

Shares of NASDAQ VERA opened at $48.54 on Wednesday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.43 and a current ratio of 21.43. The firm has a market capitalization of $2.66 billion, a price-to-earnings ratio of -18.60 and a beta of 1.03. The stock has a 50 day moving average price of $41.95 and a 200 day moving average price of $39.29. Vera Therapeutics, Inc. has a 52-week low of $11.69 and a 52-week high of $50.78.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.21). Sell-side analysts expect that Vera Therapeutics, Inc. will post -2.55 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Guggenheim lifted their price target on Vera Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research report on Monday, October 28th. JPMorgan Chase & Co. lifted their price target on Vera Therapeutics from $72.00 to $75.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Wedbush lifted their price target on Vera Therapeutics from $30.00 to $38.00 and gave the stock a “neutral” rating in a research report on Friday, November 8th. Evercore ISI upgraded Vera Therapeutics to a “strong-buy” rating in a research report on Monday, September 16th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $107.00 target price on shares of Vera Therapeutics in a research report on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $57.88.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.